Innovator companies looking to enter or extend their presence in the dynamic market for gene therapies and CAR-T and associated cell therapies need a complete understanding of the market dynamics and the landscape of providers capable of manufacturing plasmids and AAV and lentiviral vectors.
Nice Insight’s 2021 Cell & Gene Therapy Report & Pricing Study is an ideal resource for innovators looking to outsource plasmid and viral vector manufacturing to support cell and gene therapy programs, providing profiles of relevant providers and pricing benchmarks for a range of relevant line items. Understand the market of outsourcing providers and what you should pay with competitive pricing comparisons for plasmid and viral vector manufacturing.
For CDMOs working in the plasmid and viral vector manufacturing space and PE companies and investors plotting out investment strategies within this evolving market, our 2021 Cell & Gene Therapy Report & Pricing Study will help you position your company within the competitive landscape, benchmark your pricing structures against your peers and competitors, and better align your offering with customers’ needs now and into the future. The report will help you assess how you measure up in the marketplace and aid your ongoing business development strategy. Acquire pricing data that is not available elsewhere, at any price.